Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 20;19:162. doi: 10.1186/s12974-022-02525-8

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 8 — Microinjection of anti-CX3CL1 antibody into ACC attenuates SNI-induced mechanical allodynia and inhibits ACC TNF-α and Nav1.6 protein upregulations. A, B Behavioral test paradigms are shown on the first left, and the ipsilateral and contralateral test results are shown on the second and first right, respectively. Statistical significance was determined by Dunn's multiple comparisons test (*p < 0.05; **p < 0.01 versus PO -1d) or multiple t tests (#p < 0.05 versus IgG control). C The mark left by the cannula implantation showing the drug injection site in Cg1 region. D Representative western blotting of CX3CL1, TNF-α and Nav1.6 in bilateral ACC following contralateral administration of anti-CX3CL1 antibody (1 μg/μl, 3 μl) 7d post-SNI. E The quantification results showing the inhibitory effects of anti-CX3CL1 antibody on SNI-induced CX3CL1, TNF-α and Nav1.6 expressions. *p < 0.05, **p < 0.01, ***p < 0.001 versus IgG control (one-way ANOVA)